



Phone: (305) 306-7147  
Fax: (305) 442-9559  
Email: intake@clearwellinfusion.com

# OCREVUS (ocrelizumab)

## PATIENT DEMOGRAPHICS

Patient Name: \_\_\_\_\_  
Date of Birth: \_\_\_\_\_ M: ☐ F: ☐ Address: \_\_\_\_\_  
Phone: \_\_\_\_\_ City, State, Zip: \_\_\_\_\_  
Email: \_\_\_\_\_

Allergies: \_\_\_\_\_

## PRIMARY DIAGNOSIS

ICD-10 Code: \_\_\_\_\_

## DOCUMENTATION (PLEASE ATTACH)

### Clinical / Progress Notes, Labs, Tests supporting primary diagnosis

- ☐ Hepatitis B virus screening (HBsAg and anti-HBc) prior to therapy initiation required  
Date performed: \_\_\_\_\_ ☐ Negative ☐ Positive  
☐ Quantitative serum immunoglobulin test during treatment and after discontinuation of treatment,  
until B-cell repletion, and especially in the setting of recurrent serious infections  
☐ Pregnancy test (if applicable)

**Clearwell Infusion Centers will draw maintenance labs unless otherwise directed by Referring Provider**

## PRE-MEDICATION

- ☐ Acetaminophen 1000mg PO ☐ Other: \_\_\_\_\_  
☐ Cetirizine 10mg PO

## PRIMARY MEDICATION ORDER

### Dosage

- ☐ 300mg IV initial dose, followed by 2 weeks later by a second 300mg IV dose  
subsequent to first 2 doses, 600mg IV does every 6 months

### Premedication Per Prescribing Information

- ☐ Solu-medrol 100mg IV 30 minutes prior to each treatment  
☐ Diphenhydramine 25mg PO 30-60 minutes prior to each treatment

### Patient Weight:

\_\_\_\_\_  
lbs  
\_\_\_\_\_  
kg

## NOTES

\_\_\_\_\_

## ORDERING PROVIDER

Provider Name: \_\_\_\_\_ NPI: \_\_\_\_\_  
Practice Name: \_\_\_\_\_ Phone: \_\_\_\_\_  
Office Contact: \_\_\_\_\_ Fax: \_\_\_\_\_  
Practice Address: \_\_\_\_\_  
City, State, Zip: \_\_\_\_\_

Provider Signature: \_\_\_\_\_ Date: \_\_\_\_\_